Published in J Immunol on June 01, 1984
Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol (1985) 3.31
Estrogen administration activates extrathymic T cell differentiation in the liver. J Exp Med (1992) 1.38
Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J (1995) 1.99
Aetiology of Kaposi's sarcoma. Lancet (1990) 1.95
Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J (1995) 1.54
Long-term effects of neonatal estrogen treatment on mitogen responsiveness of mouse spleen lymphocytes. J Natl Cancer Inst (1979) 1.49
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med (1995) 1.30
A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cells. J Immunol (1991) 1.29
Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. J Immunol (1997) 1.29
Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol (1970) 1.22
Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A (1991) 1.22
The effect of estrogen on the incorporation of 3H-thymidine by PHA-stimulated human peripheral blood lymphocytes. J Immunol (1974) 1.21
In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa B transcription factors. Proc Natl Acad Sci U S A (1996) 1.21
Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol (1970) 1.18
Stimulation of human naive and memory T helper cells with bacterial superantigen. Naive CD4+45RA+ T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway. J Immunol (1992) 1.17
Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology (1993) 1.13
Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. J Immunol (1987) 1.13
Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer (1993) 1.11
Superantigens anergize cytokine production but not cytotoxicity in vivo. Immunology (1994) 1.10
Thymus-specific antigens on human thymocytes and on thymic-derived lymphocytes. Transplantation (1973) 1.10
Immunologic studies of normal, benign, and malignant human prostatic tissue. Cancer (1972) 1.09
IgE in pemphigus. Arch Dermatol (1977) 1.09
Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor. Eur J Immunol (1991) 1.09
T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol (1995) 1.07
Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol (1985) 1.06
Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol (1996) 1.05
Precipitating antigens of the normal human prostate. J Reprod Fertil (1970) 1.04
Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother (1993) 1.03
Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci U S A (1995) 1.03
Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology (1990) 1.03
Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol (1997) 1.02
Pemphigus-like antibodies in patients with skin burns. Vox Sang (1969) 1.02
Staphylococcal-enterotoxin-dependent cell-mediated cytotoxicity. Immunol Today (1991) 1.01
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother (1995) 0.99
Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release. Cell Immunol (1996) 0.99
Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate. Exp Med Surg (1969) 0.98
Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Am J Pathol (1997) 0.98
Serum proteins in patients with benign and malignant diseases of the prostate. Neoplasma (1971) 0.97
Blood product immunosuppression and the acquired immunodeficiency syndrome. Ann Intern Med (1986) 0.97
Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol (1993) 0.95
Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res (1986) 0.95
Histamine inhibits interleukin 1 production by lipopolysaccharide-stimulated human peripheral blood monocytes. Scand J Immunol (1988) 0.95
The LFA-3 adhesion pathway is differently utilized by superantigen-activated human CD4+ T-cell subsets. Scand J Immunol (1992) 0.94
Effect of estrogen and corticosterone on the lymphoid system in neonatal mice. Exp Mol Pathol (1978) 0.93
Superantigen-induced anergy in cytotoxic CD8+ T cells. J Immunol (1995) 0.92
Role of the adhesion molecule ICAM-1 (CD54) in staphylococcal enterotoxin-mediated cytotoxicity. Eur J Immunol (1991) 0.92
Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur J Immunol (1994) 0.91
Genetically engineered superantigens as tolerable antitumor agents. Proc Natl Acad Sci U S A (1997) 0.91
Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR+ mononuclear leukocytes and freshly prepared leukemia cells. Cell Immunol (1990) 0.91
Alterations of alpha2-globulin and the clinical response in patients with prostatic cancer following cryotherapy. Oncology (1975) 0.91
Localization of immunoglobulins in human prostatic tissue. J Immunol (1971) 0.90
Tissue- and species-specific antibodies in antithymocyte globulin. Transplantation (1972) 0.90
Reduced natural killer activity in female mice after neonatal exposure to diethylstilbestrol. J Immunol (1980) 0.89
Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity. Immunology (1993) 0.89
Hormonal therapy and alteration of lymphocyte proliferation. J Lab Clin Med (1976) 0.89
Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate. Cancer Res (1978) 0.89
The role of B7-1 and LFA-3 in costimulation of CD8+ T cells. J Immunol (1997) 0.88
Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth. Int J Cancer (1998) 0.88
Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem (1993) 0.88
The female prostate and prostate-specific antigen. Immunohistochemical localization, implications of this prostate marker in women and reasons for using the term "prostate" in the human female. Histol Histopathol (2000) 0.87
Condylomata acuminata: treatment by autogenous vaccine. IMJ Ill Med J (1975) 0.87
Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am J Reprod Immunol Microbiol (1985) 0.87
Immunochemical characterization of epithelial antigen(s) reactive with pemphigus-like antibodies of rabbit and human pemphigus autoantibodies. J Hyg Epidemiol Microbiol Immunol (1969) 0.87
Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II. J Immunol (1996) 0.87
Monocyte-regulated IFN-gamma production in human T cells involves CD2 signaling. J Immunol (1993) 0.86
Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity. J Immunol (1996) 0.86
Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Cancer Res (1995) 0.86
Natural killer cell activity and tumor susceptibility in female mice treated neonatally with diethylstilbestrol. Cancer Res (1981) 0.86
Cancer, immunological surveillance, and 2 -globulin. Lancet (1972) 0.86
Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol (1998) 0.85
Decreased and disproportionate T-cell population in adult mice after neonatal exposure to diethylstilbestrol. Cell Immunol (1980) 0.85
Overexpression of the T-cell receptor V beta 3 in transgenic mice increases mortality during infection by enterotoxin A-producing Staphylococcus aureus. Infect Immun (1995) 0.85
Costimulation of human CD4+ T lymphocytes with B7 and lymphocyte function-associated antigen-3 results in distinct cell activation profiles. J Immunol (1994) 0.85
Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Int J Cancer (1995) 0.85
Leukocyte adherence inhibition and immunoreactivity in prostatic cancer. I. Identification of anti-tumour cell-mediated immunity and "blocking" factor. Eur J Cancer (1977) 0.85
Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. Blood (1993) 0.84
A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. Blood (1997) 0.84
Lipofuscin granules in normal, benign and malignant human prostatic tissue. Urol Res (1973) 0.84
Generation of natural killer cells from bone marrow precursors in vitro. Immunology (1986) 0.84
Transglutaminase: co-factor in aetiology of AIDS? Lancet (1985) 0.83
Independent regulation of IFN-gamma and tumor necrosis factor by IL-1 in human T helper cells. J Immunol (1990) 0.83
Alterations of antibody response in female mice after neonatal exposure to diethylstilbestrol. J Immunol (1980) 0.83
Neonatal estrogen treatment and epithelial abnormalities in the cervicovaginal epithelium of adult mice. Cancer Res (1981) 0.83
Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue sections. J Immunol Methods (1997) 0.83
Immunopathologic studies of experimental pemphigus-like autoantibodies and bullous-like lesions. J Invest Dermatol (1969) 0.83
A tissue type transglutaminase in human seminal plasma. Am J Reprod Immunol (1997) 0.82
Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J Neuroimmunol (1997) 0.82
In vivo bound immunoglobulins in the human prostate--their identification and possible significance. Z Immunitatsforsch Exp Klin Immunol (1972) 0.82
Immune response during tumor therapy with antibody-superantigen fusion proteins. Int J Cancer (1996) 0.82
Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat. Immunopharmacology (1986) 0.82
Prostaglandin modulation of prostate tumor growth and metastases. Anticancer Res (1986) 0.82
A retrospective look at studies on prostate-specific antigen. Clin Chem (1985) 0.82
Molecular characterization and role in T cell activation of staphylococcal enterotoxin A binding to the HLA-DR alpha-chain. J Immunol (1997) 0.82
Delayed hypersensitivity response to oxazolone in neonatally estrogenized mice. Cancer Lett (1978) 0.82
Immunosuppression of cell- and serum-medicated tumour-associated immunity in prostatic cancer by human seminal plasma. Eur J Cancer (1980) 0.82
Adjuvant immunotherapy (BCG) in stage D prostate cancer. Am J Clin Oncol (1982) 0.82
T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens. Cancer Immunol Immunother (1993) 0.82
Exposure of neonatal female mice to diethylstilbestrol persistently impairs NK activity through reduction of effector cells at the bone marrow level. Immunopharmacology (1984) 0.81
Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease. Thromb Haemost (1988) 0.81
3-methylcholanthrene: transient inhibition of the lytic step of mouse natural killer cells. J Natl Cancer Inst (1983) 0.81